Mahmoud Elkaramany*

Consultant Gastroenterology, Hull Royal Infirmary, England

*Corresponding Author: Mahmoud Elkaramany, Consultant Gastroenterology, Hull Royal Infirmary, England.

Received: July 04, 2025; Published:July 04, 2025

Abstract

Corticosteroids remain a cornerstone in the management of acute flares of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Despite their effectiveness in inducing remission, systemic steroids are associated with substantial side effects, prompting the development of locally acting corticosteroids such as budesonide and rectal formulations. This article reviews the indications, benefits, and limitations of corticosteroid use in IBD, with a focus on appropriate selection and precautions in clinical practice.

Keywords: Corticosteroid; IBD; Budesonide; Localized Therapies

References

1. Greenberg GR., et al. “A Controlled Trial of a Budesonide–Formulated Controlled-Release Capsule in Active Crohn’s Disease”. NEJM (1994).
2. Sandborn WJ., et al. “Budesonide MMX in the Treatment of Mild-to-Moderate Ulcerative Colitis”. Gastroenterology (2012).
3. D’Haens GR., et al. “Budesonide for Induction of Remission in Crohn’s Disease”. Cochrane Review (2008).
4. Marteau P., et al. “Budesonide enema versus 5-ASA enema in active distal ulcerative colitis”. Alimentary Pharmacology and Therapeutics (1998).
5. ECCO Guidelines. “AGA Clinical Guidelines on UC and CD Management.

Citation

Citation: Mahmoud Elkaramany. “Corticosteroid Use in IBD: Focus on Budesonide and Localized Therapies".Acta Scientific Gastrointestinal Disorders 8.8 (2025): 10-12.

Copyright

Copyright: © 2025 Mahmoud Elkaramany. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.